GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NIOX Group PLC (OTCPK:CSSPF) » Definitions » COGS-to-Revenue

NIOX Group (NIOX Group) COGS-to-Revenue : 0.29 (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is NIOX Group COGS-to-Revenue?

NIOX Group's Cost of Goods Sold for the six months ended in Dec. 2023 was $6.58 Mil. Its Revenue for the six months ended in Dec. 2023 was $22.79 Mil.

NIOX Group's COGS to Revenue for the six months ended in Dec. 2023 was 0.29.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. NIOX Group's Gross Margin % for the six months ended in Dec. 2023 was 71.11%.


NIOX Group COGS-to-Revenue Historical Data

The historical data trend for NIOX Group's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NIOX Group COGS-to-Revenue Chart

NIOX Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.26 0.32 0.32 0.29 0.28

NIOX Group Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.32 0.29 0.29 0.27 0.29

NIOX Group COGS-to-Revenue Calculation

NIOX Group's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=13.038 / 46.582
=0.28

NIOX Group's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=6.582 / 22.785
=0.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NIOX Group  (OTCPK:CSSPF) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

NIOX Group's Gross Margin % for the six months ended in Dec. 2023 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 6.582 / 22.785
=71.11 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


NIOX Group COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of NIOX Group's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


NIOX Group (NIOX Group) Business Description

Traded in Other Exchanges
Address
Edmund Halley Road, Hayakawa Building, The Oxford Science Park, Oxford, GBR, OX4 4GB
NIOX Group PLC is a medical device company that develops a range of therapies for asthma, chronic obstructive pulmonary disease, and allergy. The company has a single operating segment: NIOX. The NIOX segment relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide (FeNO). Geographically, it derives a majority of its revenue from the Asia Pacific and also has a presence in the European Union, the United States, the United Kingdom, and the Rest of the world.

NIOX Group (NIOX Group) Headlines